Are mutations in specific codons of the KRAS oncogene associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma?
Mutations in different KRAS codons may have different effects on rectal cancer resistance to CRT. This variable resistance may be related to a different frequency of TP53 mutations in KRAS mutant tumors.
Using serum analytes as surrogates for organ injury, it appears preeclampsia infrequently affects the pancreas.